URGN · CIK 1668243
What UroGen Pharma Ltd. told the SEC could break it.
UroGen is concentrated at both ends of its business. It sells Jelmyto and Zusduri through just two specialty distributors, and its largest customer was about 76% of product sales in 2025 (over 90% in 2024); on the supply side it relies on single-source suppliers for RTGel and the ureteral catheter and injector needed to deliver those drugs, so an interruption at either end could impair commercialization. Its operations add geopolitical and currency exposure — R&D and significant operations are in Israel, subject to the regional conflict and to NIS/dollar swings (the dollar fell about 12.5% against the shekel in 2025). And because its contract manufacturers sit in Israel, the Czech Republic and Belgium, pharmaceutical-specific tariffs on imported raw materials and finished product could materially raise its costs.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- Largest customer = ~76% of product sales (specialty distributor)high
UroGen sells Jelmyto and Zusduri through only two specialty distributors; its largest customer represented ~76% of product sales in 2025 (over 90% in 2024) and ~59% of receivables, an acute single-distributor concentration.
“The Company's largest customer comprises approximately 76 % and over 90 % of product sales for the twelve months ended December 31, 2025 and 2024, respectively.”
SEC filing →As of 2026
Sole-source dependency
- Single-source RTGel, ureteral catheter and injector delivery componentshigh
UroGen uses single-source suppliers for RTGel, the ureteral catheter and the injector required to deliver Jelmyto and Zusduri; supply interruption could impair commercialization.
“We currently use single source suppliers relative to production of the RTGel products, the ureteral catheter and injector which are required to be used in the delivery of Jelmyto and the ureteral catheter used in the delivery of Zusduri .”
SEC filing →As of 2026
Geographic concentration
- Israel-based operations (conflict and NIS FX)medium
UroGen's R&D and significant operations are in Israel, exposing it to the Israel-Hamas/regional conflict and to NIS/dollar swings (the dollar depreciated ~12.5% against the NIS in 2025).
“Our research and development and other significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military conditions in Israel.”
Regulatory & policy
- Pharmaceutical-specific tariffs on raw materials/APIsmedium
UroGen's CMOs are located in Israel, the Czech Republic and Belgium; pharmaceutical-specific tariffs and trade-policy changes on imported raw materials and finished drug product could materially raise its costs.
“Tariff policies, particularly those affecting the raw materials we use and pharmaceutical products, could materially increase our costs.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Teva Pharmaceutical Industries Ltd.
“We currently depend on Teva Pharmaceuticals Industries Ltd, as our single-source supplier of mitomycin API for Jelmyto, Zusduri, UGN-103 and UGN-104.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch